Extracellular HIV type 1 tat protein induces CD69 expression through NF- κB activation: Possible correlation with cell surface Tat-binding proteins

AIDS Research and Human Retroviruses

Volumn 15, Issue 13, 1999, Pages 1209-1218

  Blázquez, M Valle ^a   Macho, Antonio ^a   Ortiz, Carmen ^a   Lucena, Concepción ^a   López Cabrera, Manuel ^b   Sánchez Madrid, Francisco ^b   Muñoz, Eduardo ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; VIRUS REPLICATION;

ANTIGENS, CD; BLOTTING, WESTERN; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; GENE PRODUCTS, TAT; HIV-1; HUMANS; K562 CELLS; NF-KAPPA B; TERMINAL REPEAT SEQUENCES; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 2442731878     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310304     Document Type: Article

References (66)

1. Vaishnav YN and Wong-Staal F: The biochemistry of AIDS. Annu Rev Biochem 1991;60:578-630.
2. Jones KA: Tat and the HIV-1 promoter. Curr Opin Cell Biol 1993;5:461-468.
3. Jones KA and Peterlin BM: Control of RNA initiation and elongation at the HIV-1 promoter. Annu Rev Biochem 1994;63: 717-743.
4. Peterlin BM, Adams M, Alonso A, Baur A, Ghosh S, Lu X, and Luo Y: Tat trans-activator. In Human Retroviruses (Cullen BR, ed.). IRL Press, Oxford, 1993.
5. Kuppuswamy M, Subramanian T, Srinivasan A, and Chinnadurai G: Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res 1989;17: 3551-3561.
6. Rhim H, Echetebu CO, Hermann CH, and Rice AP: Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione-S-transferase. J Acquir Immune Defic Syndr 1994;7:1116-1121.
7. Barillari G, Gendelman R, Gallo RC, and Ensoli B: The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993;90:7941-7945.
8. Brake DA, Debouck C, and Biesecker G: Identification of an Arg-Gly-Asp (RGD) cell adhesion site human immunodeficiency virus type 1 transactivation protein, Tat. J Cell Biol 1990;111:1275-1281.
9. 5 integrin to the basic domain of the HIV Tat protein and vitronectin. J Cell Biol 1993;121:461-468.
10. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, and Wong-Staal F: Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (London) 1990;345:84-86.
11. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, and Gallo RC: Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277-287.
12. Frankel AD and Pabo CO: Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 1988;55:1189-1193.
13. Taylor JP, Cupp C, Diaz A, Chowdhury M, Khalili K, Jimenez SA, and Amini S: Activation of expression of genes coding for extracellular matrix proteins in Tat-producing glioblastoma cells. Proc Natl Acad Sci USA 1992;89:9617-9621.
14. Viscidi RP, Mayur K, Lederman HM, and Frankel AD: Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;4937:1606-1608.
15. Subramanyam M, Gutheil WG, Bachovchin WW, and Huber BT: Mechanism of HIV-1 Tat induced inhibition of antigen-specific. T cell responsiveness. J Immunol 1993;150:2544-2553.
16. Huang L, Li CJ, and Pardee AB: Human immunodeficiency virus type-1 TAT protein activates B lymphocytes. Biochem Biophys Res Commun 1997;237:461-464.
17. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, and Ensoli B: Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992;66:7159-7167.
18. Gibellini D, Zauli G, Re MC, Milani D, Furlini G, Caramelli E, Capitani S, and La Placa M: Recombinant human immunodeficiency virus type-1 (HIV-1) Tat protein sequentially up-regulates IL-6 and TGF-β-1 mRNA expression and protein synthesis in peripheral blood monocytes. Br J Haematol 1994;88:261-267.
19. Ott M, Lovett JL, Mueller L, and Verdin E: Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-κB factors. J Immunol 1998;160:2872-2880.
20. Husain SR, Leland P, Aggarwal BB, and Puri RK: Transcriptional up-regulation of interleukin 4 receptors by human immunodeficiency virus type-1 ta: gene. AIDS Res Hum Retroviruses 1996; 12:1349-1359.
21. Hofman FM, Wright AD, Dohadwala MM, Wong-Staal F, and Walker SM: Exogenous Tat protein activates human endothelial cells. Blood 1993;82:2774-2780.
22. Dhawan S, Puri RK, Kumar A, Duplan H, Masson JM, and Aggarwal BB: Human immunodeficiency virus-1-Tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood 1997;90: 1535-1544.
23. Mann DA and Frankel AD: Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J 1991;10:1733-1739.
24. Conant K, Ma M, Nath A, and Major EO: Extracellular human immunodeficiency virus type 1 Tat protein is associated with an increase in both NF-κB binding and protein kinase C activity in primary human astrocytes. J Virol 1996;70:1384-1389.
25. Celeghini C, Marchisio M, Mischiati C, Bertolaso L, Capitani S, and Zauli G: In-vivo and in-vitro modulatory effect of human-immunodeficiency-virus type-1 (HIV-1) TAT protein on protein-kinase-C activity. Int J Oncol 1996;8:349-354.
26. Nath A, Psooy K, Martin C, Knudsen B, Magnuson DS, Haughey N, and Geiger JD: Identification of human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J Virol 1996;70:1475-1480.
27. Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, and Capitani S: Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinosiol 3-kinase in PC12 neuronal cells. J Biol Chem 1996;271:22961-22964.
28. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, Li YZ, and Pardee AB: Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997;94:8116-8120.
29. Zauli G, Previati M, Caramelli E, Bassini A, Falcieri E, Gibellini D, Bertolaso L, Bosco D, Robuffo I, and Capitani S: Exogenous human immunodeficiency virus type-1 Tat protein selectively stimulates a phosphatidylinositol-specific phospholipase C nuclear pathway in the Jurkat T cell line. Eur J Immunol 1995;25:2695-2700.
30. Sen R and Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer seuqences. Cell 1986;46:705-716.
31. Baeuerle PA and Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-179.
32. Stancovski I and Baltimore D: NF-κB activation: The IκB kinase revealed? Cell 1997;91:299-302.
33. Finco TS and Baldwin AS: Mechanistic aspects of NF-κB regulation: The emerging role of phosphorylation and proteolysis. Immunity 1995;3:263-272.
34. Ramazzotti E, Vignoli M, Re MC, Furlini G, and La Placa M: Enhanced nuclear factor-kappa B activation induced by tumour necrosis factor-alpha in stably tat-transfected cells is associated with the presence of cell-surface-bound Tat protein. AIDS 1996;10:455-461.
35. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, Dröge W, and Lehmann V: HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state. EMBO J 1995;14:546-554.
36. Demarchi F, dqAdda di Fagagna F, Falaschi A, and Giacca M: Activation of transcription factor NF-κB by the Tat protein of human immunodeficiency virus type 1. J Virol 1996;70:4427-4437.
37. Sanchez-Mateos P and Sanchez-Madrid F: Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur J Immunol 1991;21:2317-2325.
38. Cebrian M, Yague E, Rincon M, Lopez-Botet M, de Landazuri MO, and Sanchez-Madrid F: Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988;168:1621-1637.
39. Hara T, Jung LK, Bjorndahl JM, and Fu SM: Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med 1986;164: 1988-2005.
40. Ramirez R, Carracedo J, Castedo M, Zamzami N, and Kroemer G: CD69-induced monocyte apoptosis involves multiple nonredundant signaling pathways. Cell Immunol 1996;172:192-199.
41. Nakamura S, Sung SS, Bjorndahl JM, and Fu SM: Human T cell activation. IV. T cell activation and proliferation via the early activation antigen EA 1. J Exp Med 1989;169:677-689.
42. Testi R, Phillips JH, and Lanier LL: T cell activation via Leu-23 (CD69). J Immunol 1989;143:1123-1128.
43. Santis AG, Campanero MR, Alonso JL, Tugores A, Alonso MA, Yague E, Pivel JP, and Sanchez-Madrid F: Tumor necrosis factor-alpha production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur J Immunol 1992;22:1253-1259.
44. Tugores A, Alonso MA, Sanchez-Madrid F, and de Landazuri MO: Human T cell activation through the activation-inducer molecule/CD69 enhances the activity of transcription factor AP-1. J Immunol 1992;148:2300-2306.
45. López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, and Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993;178:537-547.
46. López-Cabrera M, Muñoz E, Blázquez MV, Ursa MA, Santis AG, and Sánchez-Madrid F: Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-alpha-responsive elements. J Biol Chem 1995;270:21545-21551.
47. Muñoz E, Courtois G, Veschambre P, Jalinot P, and Israel A: Tax induces nuclear translocation of NF-kappa B through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of I kappa B alpha/MAD3. J Virol 1994;68: 8035-8044.
48. Castellanos MC, Muñoz C, Montoya MC, Lara-Pezzi E, López-Cabrera M, and de Landazuri MO: Expression of the leukocyte early activation antigen CD69 is regulated by the transcription factor AP-1. J Immunol 1997;159:5463-5473.
49. Alcami J, Lain de Lera T, Folgueira L, Pedraza MA, Jacque JM, Bachelerie F, Noriega AR, Hay RT, Harrich D, Gaynor RB, et al.: Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes. EMBO J 1995;14:1552-1560.
50. Beauparlant P, Kwon H. Clarke M, Lin R, Sonenberg N, Wainberg M, and Hiscott J: Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication. J Virol 1996;70:5777-5785.
51. Harhaj E, Blaney J, Millhouse S, and Sun SC: Differential effects of I kappa B molecules on Tat-mediated transactivation of HIV-1 LTR. Virology 1996;216:284-287.
52. Wei P, Garber ME, Fang SM, Fischer WH, and Jones KA: A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998;92:451-462.
53. Yang X, Gold MO, Tang DN, Lewis DE, Aguillar-Cordova E, Rice AP, and Herrmann CH: TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines. Proc Natl Acad Sci USA 1997;94:12331-12336.
54. Gatignol A, Duarte M, Daviet L, Chang YN, and Jeang KT: Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr 1996;5:217-228.
55. Huang LM and Jeang KT: Increased spacing between Sp1 and TATAA renders human immunodeficiency virus type 1 replication defective: Implication for Tat function. J Virol 1993;67:6937-6944.
56. Kashanchi F, Piras G, Radonovich MF, Duvall JF, Fattaey A, Chiang CM, Roeder RG, and Brady JN: Direct interaction of human TFIID with the HIV-1 transactivator Tat. Nature (London) 1994; 367:295-299.
57. Plaksin D, Baeuerle PA, and Eisenbach L: KBF1 (p50 NF-κB homodimer) acts as a represser of H-2Kb gene expression in metastatic tumor cells. J Exp Med 1993;177:1651-1662.
58. - T lymphocytes. Science 1992;256: 1452-1456.
59. Ursini MV, Lettieri T, Braddock M, and Martini G: Enhanced activity of human G6PD promoter transfected in HeLa cells producing high levels of HIV-1 Tat. Virology 1993;196:338-343.
60. Chen P, Mayne M, Power C, and Nath A: The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem 1997;272: 22385-22388.
61. Westendrop MO, Li-Weber M, Frank RW, and Krammer PH: Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 1994;88:4177-4185.
62. Juliano RL and Haskill S; Signal transduction from the extracellular matrix. J Cell Biol 1993;120:577-585.
63. Gutheil W, Subramanyam M, Flentke G, Sanford D, Munoz E, Huber B, and Bachovchin W: Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): A possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 1994;91:6594-6598.
64. Wrenger S, Hoffmann T, Faust J, Mrestani-Klaus C, Brandt W, Neubert K, Kraft M, Olek S, Frank R, Ansorge S, and Reinhold D: The N-terminal structure of HIV-1 Tat is required for suppression of CD28-dependent T cell growth. J Biol Chem 1997;272: 30283-30288.
65. Flentke GR, Muñoz E, Huber BT, Plant AG, Kettner CA, and Bachovchin WW: Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 1991;88:1556-1559.
66. Weeks BS, Desai K, Loewenstein PM, Klotman ME, Klotman PE, Green M, and Kleinman HK: Identification of a novel cell attachment domain in the HIV-1 Tat protein and its 90-kDa cell surface binding protein. J Biol Chem 1993;268:5279-5284.